Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

NCT02574455 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

529

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Sacituzumab govitecan
DRUG: Eribulin
DRUG: Capecitabine
DRUG: Gemcitabine
DRUG: Vinorelbine

Sponsor

Gilead Sciences